230 related articles for article (PubMed ID: 12754054)
21. Mechanism of relaxation and interaction with nitric oxide of the soluble guanylate cyclase stimulator BAY 41-2272 in mouse gastric fundus and colon.
Cosyns SM; Lefebvre RA
Eur J Pharmacol; 2012 Jul; 686(1-3):104-15. PubMed ID: 22575520
[TBL] [Abstract][Full Text] [Related]
22. BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase.
Koglin M; Stasch JP; Behrends S
Biochem Biophys Res Commun; 2002 Apr; 292(4):1057-62. PubMed ID: 11944922
[TBL] [Abstract][Full Text] [Related]
23. Effects of BAY 41-2272, an activator of nitric oxide-independent site of soluble guanylate cyclase, on human NADPH oxidase system from THP-1 cells.
Borges de Oliveira-Junior E; Thomazzi SM; Rehder J; Antunes E; Condino-Neto A
Eur J Pharmacol; 2007 Jul; 567(1-2):43-9. PubMed ID: 17499238
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms underlying relaxation of rabbit aorta by BAY 41-2272, a nitric oxide-independent soluble guanylate cyclase activator.
Priviero FB; Baracat JS; Teixeira CE; Claudino MA; De Nucci G; Antunes E
Clin Exp Pharmacol Physiol; 2005 Sep; 32(9):728-34. PubMed ID: 16173929
[TBL] [Abstract][Full Text] [Related]
25. Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase.
Schrammel A; Behrends S; Schmidt K; Koesling D; Mayer B
Mol Pharmacol; 1996 Jul; 50(1):1-5. PubMed ID: 8700100
[TBL] [Abstract][Full Text] [Related]
26. Effect of soluble guanylyl cyclase activator and stimulator therapy on nitroglycerin-induced nitrate tolerance in rats.
Jabs A; Oelze M; Mikhed Y; Stamm P; Kröller-Schön S; Welschof P; Jansen T; Hausding M; Kopp M; Steven S; Schulz E; Stasch JP; Münzel T; Daiber A
Vascul Pharmacol; 2015 Aug; 71():181-91. PubMed ID: 25869522
[TBL] [Abstract][Full Text] [Related]
27. Effects of 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-ylamine (BAY 41-2272) on smooth muscle tone, soluble guanylyl cyclase activity, and NADPH oxidase activity/expression in corpus cavernosum from wild-type, neuronal, and endothelial nitric-oxide synthase null mice.
Teixeira CE; Priviero FB; Webb RC
J Pharmacol Exp Ther; 2007 Sep; 322(3):1093-102. PubMed ID: 17596536
[TBL] [Abstract][Full Text] [Related]
28. The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide.
Roger S; Badier-Commander C; Paysant J; Cordi A; Verbeuren TJ; Félétou M
Br J Pharmacol; 2010 Nov; 161(5):1044-58. PubMed ID: 20977455
[TBL] [Abstract][Full Text] [Related]
29. A constitutively activated mutant of human soluble guanylyl cyclase (sGC): implication for the mechanism of sGC activation.
Martin E; Sharina I; Kots A; Murad F
Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9208-13. PubMed ID: 12883009
[TBL] [Abstract][Full Text] [Related]
30. NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size.
Bice JS; Keim Y; Stasch JP; Baxter GF
Cardiovasc Res; 2014 Feb; 101(2):220-8. PubMed ID: 24259501
[TBL] [Abstract][Full Text] [Related]
31. Insights into soluble guanylyl cyclase activation derived from improved heme-mimetics.
Rekowski MVW; Kumar V; Zhou Z; Moschner J; Marazioti A; Bantzi M; Spyroulias GA; van den Akker F; Giannis A; Papapetropoulos A
J Med Chem; 2013 Nov; 56(21):8948-8952. PubMed ID: 24090476
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the relaxant effect of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in isolated detrusor smooth muscle.
Báu FR; Mónica FZ; Priviero FB; Baldissera L; de Nucci G; Antunes E
Eur J Pharmacol; 2010 Jul; 637(1-3):171-7. PubMed ID: 20399768
[TBL] [Abstract][Full Text] [Related]
33. Nitric oxide and heat shock protein 90 activate soluble guanylate cyclase by driving rapid change in its subunit interactions and heme content.
Ghosh A; Stasch JP; Papapetropoulos A; Stuehr DJ
J Biol Chem; 2014 May; 289(22):15259-71. PubMed ID: 24733395
[TBL] [Abstract][Full Text] [Related]
34. Insights into BAY 60-2770 activation and S-nitrosylation-dependent desensitization of soluble guanylyl cyclase via crystal structures of homologous nostoc H-NOX domain complexes.
Kumar V; Martin F; Hahn MG; Schaefer M; Stamler JS; Stasch JP; van den Akker F
Biochemistry; 2013 May; 52(20):3601-8. PubMed ID: 23614626
[TBL] [Abstract][Full Text] [Related]
35. Cobinamides are novel coactivators of nitric oxide receptor that target soluble guanylyl cyclase catalytic domain.
Sharina I; Sobolevsky M; Doursout MF; Gryko D; Martin E
J Pharmacol Exp Ther; 2012 Mar; 340(3):723-32. PubMed ID: 22171090
[TBL] [Abstract][Full Text] [Related]
36. Soluble guanylyl cyclase activators increase the expression of tolerance to morphine analgesic effect.
Durmus N; Bagcivan I; Ozdemir E; Altun A; Gursoy S
Bratisl Lek Listy; 2014; 115(6):334-9. PubMed ID: 25023422
[TBL] [Abstract][Full Text] [Related]
37. Acrylamide analog as a novel nitric oxide-independent soluble guanylyl cyclase activator.
Nakane M; Kolasa T; Chang R; Miller LN; Moreland RB; Brioni JD
J Pharmacol Sci; 2006 Oct; 102(2):231-8. PubMed ID: 17050951
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272.
Mullershausen F; Russwurm M; Friebe A; Koesling D
Circulation; 2004 Apr; 109(14):1711-3. PubMed ID: 15066950
[TBL] [Abstract][Full Text] [Related]
39. Effects of nitroglycerin/L-cysteine on soluble guanylate cyclase: evidence for an activation/inactivation equilibrium controlled by nitric oxide binding and haem oxidation.
Gorren AC; Russwurm M; Kollau A; Koesling D; Schmidt K; Mayer B
Biochem J; 2005 Sep; 390(Pt 2):625-31. PubMed ID: 15907191
[TBL] [Abstract][Full Text] [Related]
40. Functional role of the soluble guanylyl cyclase alpha(1) subunit in vascular smooth muscle relaxation.
Nimmegeers S; Sips P; Buys E; Brouckaert P; Van de Voorde J
Cardiovasc Res; 2007 Oct; 76(1):149-59. PubMed ID: 17610859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
